JP2011520921A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520921A5
JP2011520921A5 JP2011509790A JP2011509790A JP2011520921A5 JP 2011520921 A5 JP2011520921 A5 JP 2011520921A5 JP 2011509790 A JP2011509790 A JP 2011509790A JP 2011509790 A JP2011509790 A JP 2011509790A JP 2011520921 A5 JP2011520921 A5 JP 2011520921A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
inhibitor
anticancer drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011509790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520921A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044334 external-priority patent/WO2009140675A2/en
Publication of JP2011520921A publication Critical patent/JP2011520921A/ja
Publication of JP2011520921A5 publication Critical patent/JP2011520921A5/ja
Pending legal-status Critical Current

Links

JP2011509790A 2008-05-16 2009-05-18 抗腫瘍アルカロイドとの併用療法 Pending JP2011520921A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5372608P 2008-05-16 2008-05-16
US61/053,726 2008-05-16
PCT/US2009/044334 WO2009140675A2 (en) 2008-05-16 2009-05-18 Combination therapy with an antitumor alkaloid

Publications (2)

Publication Number Publication Date
JP2011520921A JP2011520921A (ja) 2011-07-21
JP2011520921A5 true JP2011520921A5 (https=) 2012-07-05

Family

ID=41136781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509790A Pending JP2011520921A (ja) 2008-05-16 2009-05-18 抗腫瘍アルカロイドとの併用療法

Country Status (12)

Country Link
US (1) US20110070232A1 (https=)
EP (1) EP2307003A2 (https=)
JP (1) JP2011520921A (https=)
KR (1) KR20110025178A (https=)
CN (1) CN102099025A (https=)
AU (1) AU2009246130A1 (https=)
CA (1) CA2724325A1 (https=)
IL (1) IL209361A0 (https=)
MX (1) MX2010012501A (https=)
NZ (1) NZ589269A (https=)
RU (1) RU2010151602A (https=)
WO (1) WO2009140675A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
ME02395B (me) * 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
ES3057783T3 (en) * 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
KR102260846B1 (ko) 2018-07-09 2021-06-07 국립암센터 고시폴, 펜포르민 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물
JP2023503318A (ja) 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027848A1 (en) * 1996-01-31 1997-08-07 Board Of Regents, The University Of Texas System SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
AU770309B2 (en) * 1998-06-05 2004-02-19 Regent Court Technologies Monoamine oxidase (MAO) inhibitors and uses thereof
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
JP2003520801A (ja) * 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0229793D0 (en) * 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
AU2005333515B2 (en) * 2004-07-09 2012-05-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CA2636596A1 (en) * 2005-11-04 2007-05-18 James Pluda Method of treating cancers with saha and pemetrexed
JP2009514870A (ja) * 2005-11-04 2009-04-09 ワイス mTORインヒビター、ハーセプチン、および/またはHKI−272の抗悪性腫瘍性組み合わせ
KR101108407B1 (ko) * 2006-06-21 2012-01-30 일라이 릴리 앤드 캄파니 젬시타빈 아미드 전구약물의 결정 형태, 그의 조성물 및 용도
CA2724206A1 (en) * 2008-05-16 2009-11-19 Pharma Mar S.A. Multiple myeloma treatments

Similar Documents

Publication Publication Date Title
JP2011520921A5 (https=)
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
JP2021169479A5 (https=)
Oronsky et al. What's new in SCLC? A review
Monneret Platinum anticancer drugs. From serendipity to rational design
JP2013542241A5 (https=)
Kim et al. Second-line chemotherapy for small-cell lung cancer (SCLC)
RU2006122350A (ru) Комбинированная химиотерапия
JP2020512314A5 (https=)
JP2010520289A5 (https=)
JP2011522773A5 (https=)
JP2010180210A5 (https=)
RU2013126630A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2018531226A5 (https=)
JP2019501873A5 (https=)
CN102772416A (zh) 包含GSK-3β抑制剂和SBE7-β-CD的药物组合物
NZ599878A (en) Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents
JP2021528496A5 (https=)
JP2007277240A5 (https=)
RU2008139406A (ru) Комдинированная терапия (2r, z)-2-амино-2-циклогексил-n-(1-метил-1н-пиразол-4-ил)-1-оксо-2, 6-дигидо-1н-(1, 2)диазепино(4, 5, 6-d(ндол-8-ил)ацетамидом
Bernal et al. Metal-based molecules in the treatment of cancer: From bench to bedside
Turek et al. New hopes in cancer battle-a review of new molecules and treatment strategies
JP2007531728A5 (https=)
Sun et al. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells
Hu et al. Current status of CPT and its analogues in the treatment of malignancies